Aims Denosumab, a fully human monoclonal antibody directed against RANKL, has recently been introduced in the treatment strategy of giant cell tumour of bone (GCTB). Aim of this study was to investigate the phenotypical modifications induced by denosumab treatment in a series of 15 GCTB.

Denosumab treated giant cell tumour of bone: A morphological, immunohistochemical and molecular analysis of a series / Girolami, Ilaria; Mancini, Irene; Simoni, Antonella; Baldi, Giacomo Giulio; Simi, Lisa; Campanacci, Domenico; Beltrami, Giovanni; Scoccianti, Guido; D'Arienzo, Antonio; Capanna, Rodolfo; Franchi, Alessandro. - In: JOURNAL OF CLINICAL PATHOLOGY. - ISSN 0021-9746. - STAMPA. - 69:(2016), pp. 240-247. [10.1136/jclinpath-2015-203248]

Denosumab treated giant cell tumour of bone: A morphological, immunohistochemical and molecular analysis of a series

MANCINI, IRENE;Simi, Lisa;CAMPANACCI, DOMENICO ANDREA;BELTRAMI, GIOVANNI;FRANCHI, ALESSANDRO
2016

Abstract

Aims Denosumab, a fully human monoclonal antibody directed against RANKL, has recently been introduced in the treatment strategy of giant cell tumour of bone (GCTB). Aim of this study was to investigate the phenotypical modifications induced by denosumab treatment in a series of 15 GCTB.
2016
69
240
247
Girolami, Ilaria; Mancini, Irene; Simoni, Antonella; Baldi, Giacomo Giulio; Simi, Lisa; Campanacci, Domenico; Beltrami, Giovanni; Scoccianti, Guido; D'Arienzo, Antonio; Capanna, Rodolfo; Franchi, Alessandro
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1056939
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 87
  • ???jsp.display-item.citation.isi??? 76
social impact